Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 Life Science Investing
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit Life Science Investing
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements Life Science Investing
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors Life Science Investing
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer Annual Meeting Life Science Investing
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 Life Science Investing
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th Life Science Investing
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights Life Science Investing
